Evidence map›Paper›PMID 41961470›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Hydrogen-Releasing Nanozyme Engineers a Mitochondrial ROS Amplifier for Self-Sustaining Catalytic Immunotherapy.

Mingfan Shi, Jingrui Cao, Tong Wu, Guang Yang, YaWen Yang, Shixin Zhang, Wenwen Su, Hongyu Chu, Yangyang Zhao, Shan Jiang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mingfan ShiKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Jingrui CaoHuzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang Province, China.
Tong WuThe First Research Laboratory, Changchun Institute of Biological Products Co., Ltd., Changchun, Jilin, China.
Guang YangJILIN Cancer Hospital, Changchun, Jilin, China.
YaWen YangJILIN Cancer Hospital, Changchun, Jilin, China.
Shixin ZhangKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Wenwen SuKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Hongyu ChuDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Yangyang ZhaoKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Shan JiangKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Qiong WuKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Dongxu JiaoCollege of Chemistry Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin, China.
Fangfang ChenKey Laboratory of Pathobiology Nanomedicine and Translational Research Center, Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.ORCID https://orcid.org/0000-0002-3284-3331

Funding

China-Japan Union Hospital of Jilin University MED+X Interdisciplinary Discipline Cultivation Program 2025023National Key Research and Development Program of China 2024YFA0918600National Natural Science Foundation of China 32271446Natural Science Foundation of Jilin Province 20240305029YYProgram for Jilin University Science and Technology Innovative Research Team 2019TD-36
6 · The paper itself

Abstract

The efficacy of nanocatalytic therapy is constrained by the limited availability of endogenous hydrogen peroxide (H

Indexed as

HydrogenImmunotherapyMitochondriaReactive Oxygen SpeciesAnimalsCatalysisCell Line, TumorHumansHydrogen PeroxideMiceOxidative StressPalladiumRhodiumHydrogenHydrogen PeroxidePalladiumReactive Oxygen SpeciesRhodiumhydrogen‐releasing nanozymemitochondrial reprogrammingPd‐based alloy nanohydridesprolonged oxidative stresstumor catalytic therapy

Identifiers

PMID41961470
PMCPMC13334870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.